ArticleJournal of cellular and molecular medicine2026
EN2 Regulates Pancreatic Cancer Initiation, Progression, and Epithelial-Mesenchymal Transition Through the Notch Signalling Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The incidence and mortality of pancreatic cancer are steadily increasing worldwide, and the disease is projected to become the second leading cause of cancer-related deaths by 2030. Pancreatic tumorigenesis is driven by multiple genetic alterations, underscoring the need to elucidate the molecular mechanisms underlying pancreatic carcinogenesis. In this context, the present study is the first to identify a novel oncogenic role for Engrailed 2 (EN2) in the initiation and progression of pancreatic cancer and to characterise its underlying molecular pathogenesis. Immunohistochemical analysis of a pancreatic cancer tissue microarray revealed significantly elevated EN2 expression in tumour tissues compared with adjacent normal tissues. Consistent with these findings, EN2 was markedly upregulated in human pancreatic cancer cell lines, but absent in normal pancreatic epithelial cells, and functional studies demonstrated that EN2 expression is oncogenic in pancreatic cancer. TCGA data further corroborated the significantly higher EN2 expression in pancreatic cancer tissues and showed that elevated EN2 levels are associated with poor overall survival. To define the biological significance of EN2, we investigated its role in promoting pancreatic cancer initiation and progression. Gain- and loss-of-function studies revealed that EN2 regulates key target genes involved in pluripotency, cell survival, and cell-cycle progression, drug resistance, and epithelial-mesenchymal transition. Moreover, lentiviral-mediated shRNA knockdown of EN2 suppressed pancreatic cancer cell proliferation, invasion, and metastasis in vitro and significantly inhibited tumour growth in a xenograft mouse model, in part by inhibiting Notch signalling. Taken together, these findings identify EN2 as a critical driver of pancreatic cancer initiation, progression, and metastasis, representing the first report of its oncogenic function in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.